Rakuten Medical Raises $100 Million as Light-Based Cancer Therapy Targets U.S. FDA Filing in 2028

Rakuten Medical is preparing to seek U.S. regulatory approval for a light-based cancer treatment that the company describes as an alternative to some surgical procedures. The Japanese biotech has set a target of filing with the Food and Drug Administration in 2028, turning an experimental technology into a multi-year clinical and regulatory effort.

The company is a biotech offshoot of Rakuten, the Japanese technology conglomerate, and is led by CEO Minami Maeda. Maeda told Fortune that the treatment asks surgeons to replace scalpels with a device he compared to a “lightsaber,” a vivid description of a therapy built around targeted light rather than conventional cutting. The Japan Times, FirstWord Pharma and CNBC also identified the United States as a central expansion goal.

Rakuten Medical’s approach combines a light-sensitive drug with an external light source to attack targeted cancer cells. After the drug binds to selected cells, illumination activates it and causes damage in the treated area. The company’s pitch centers on local precision, with treatment delivered to visible or accessible tumors rather than through a broad systemic therapy.

That mechanism places the technology between drug treatment and intervention with a device. Its clinical value will depend on evidence showing that it controls tumors, preserves surrounding tissue and improves outcomes for appropriate patients. Rakuten Group has also described work involving artificial intelligence in cancer treatment, while the company’s pipeline and corporate materials outline a broader development program. Those materials provide context for the platform, but U.S. acceptance will rest on clinical data and FDA review.

Rakuten Medical raised $100 million in an oversubscribed Series F round to accelerate development toward U.S. regulatory approval. The financing gives the company capital for clinical work, manufacturing preparation, regulatory activities and commercial planning as it approaches the planned 2028 filing.

The funding also marks a sharper transition from platform development to execution. Fierce Biotech framed the raise as financing for a path to a 2028 FDA filing, while Rakuten Medical’s announcement positioned the round as support for development aimed at U.S. approval. The company’s news and press-release pages provide the primary account of the financing, and outside coverage from Fortune and CNBC places the fundraising within its international expansion strategy.

Rakuten Medical is targeting markets closer to Japan before its U.S. launch, including Taiwan, Macau, Singapore, Hong Kong and Saudi Arabia. Those markets give the company opportunities to build clinical experience, establish treatment centers and develop physician familiarity while its American regulatory program continues.

The sequencing reflects the demands of introducing a new cancer therapy. Hospitals need trained staff, treatment protocols, equipment and reimbursement pathways, while regulators need evidence tailored to local requirements. The company’s international plans therefore involve more than geographic sales. They also create an operating base for a treatment that depends on coordinated use of a drug, a light device and trained clinical teams. Coverage from Fortune and CNBC emphasizes the global expansion plan, while Rakuten Medical’s pipeline and corporate pages describe the development infrastructure behind it.

The 2028 target is a filing goal, not an approval date. Rakuten Medical must complete the studies needed to support safety and effectiveness, assemble its regulatory submission and answer questions from FDA reviewers. The agency will assess the therapy’s benefits, risks, manufacturing controls and use instructions.

The treatment’s novelty could make clinical positioning especially important. A therapy that replaces or reduces surgery would need to show where it fits in care, which tumor types it addresses and how it compares with existing options. Doctors also need clear guidance on patient selection and light delivery. Fierce Biotech, FirstWord Pharma and CNBC all place the FDA submission on a 2028 timetable, while the company’s pipeline and press materials describe the underlying development effort without establishing an approval outcome.

Rakuten Medical’s “lightsaber” language gives the technology an accessible hook, but adoption will depend on clinical utility rather than imagery. Cancer specialists will weigh survival, recurrence, side effects, treatment time and ease of integration with surgery, radiation and drug therapies.

The company enters a field crowded with established cancer treatments and newer precision approaches. Its financing supports a serious attempt to reach the U.S. market, yet the next milestones are technical and clinical: trial progress, regulatory interactions, manufacturing readiness and results that persuade hospitals to change practice. For now, the 2028 filing target is the clearest marker of progress, with overseas market entry providing the nearer-term commercial test.